OrbiMed – a global healthcare investment firm – recently announced it has raised over $4.3 billion in commitments for its latest private investment funds, including OrbiMed Private Investments IX, OrbiMed Asia Partners V, and OrbiMed Royalty & Credit Opportunities IV. Consistent with their predecessors, the new funds enable OrbiMed to invest globally, from the seed stage for start-ups incubated by OrbiMed through growth capital opportunities.
OrbiMed works with its portfolio companies to provide tailored financing solutions, including equity, credit, and royalty-based financing. And OrbiMed focuses on innovative and growth-oriented opportunities across healthcare sub-sectors, including biopharmaceuticals, medical devices, diagnostics, and technology-enabled healthcare services.
OrbiMed is led by 21 partners, with a growing team exceeding 130 professionals that contribute diverse, complementary skills across company incubation, strategy, operations, and finance. And the firm’s professionals are based in a dozen global locations across key healthcare markets in North America, Europe, and Asia.
The investors in these new funds include a broad range of medical institutions, university endowments, foundations, pension funds, sovereign wealth funds, and family offices.
KEY QUOTE:
“OrbiMed is deeply appreciative of the continued support we’ve received from many long-standing partners who’ve invested in these funds. We will endeavor to meet our partners’ high expectations in the coming years.”
— Carter Neild, a Managing Partner of OrbiMed
